PITUITARY AND OVARIAN SUPPRESSION AFTER EARLY FOLLICULAR AND MID-LUTEAL ADMINISTRATION OF A LHRH AGONIST IN A DEPOT FORMULATION - DECAPEPTYL CR

被引：38

作者：

BROEKMANS, FJ

BERNARDUS, RE

BERKHOUT, G

SCHOEMAKER, J

机构：

[1] Division of Reproductive Endocrinology and Fertility, Department of Obstetrics and Gynecology, Vrije Universiteit, Amsterdam

来源：

GYNECOLOGICAL ENDOCRINOLOGY | 1992年 / 6卷 / 03期

关键词：

LUTEINIZING HORMONE RELEASING HORMONE AGONIST; TRIPTORELIN; PITUITARY; DEPOT FORMULATION;

D O I：

10.3109/09513599209015549

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In order to study its effect on pituitary and ovarian function, a single dose of triptorelin depot (Decapeptyl CR(R), Ferring) was administered to 12 women in the early follicular (EF,n = 6) or mid-luteal phase (ML, n = 6) of a normal cycle. In all 12 women the initial pituitary and ovarian responses were similar. Luteinizing hormone (LH) and follicle stimulating hormone (FSH) rose to peak values within 48 h, and declined to hypogonadotropic levels within 2 weeks' time. Steroid levels showed a slight to marked rise after injection and fell to hypogonadal values within 1 week. LH suppression was maintained until the 8th week after the injection, while FSH levels rose to normal between the 3rd and 4th week. Estrogen secretion started to be restored in the course of the 7th and 8th week. Menses occurred between the 11th and 13th week after the injection of the drug. This study demonstrates the possibility of rapid induction of a hypogonadotropic and hypogonadal condition in regularly cycling women by administration of a single triptorelin depot. Suppression of pituitary and ovarian function appears to be continued until the 8th week after the injection.

引用

页码：153 / 161

页数：9

共 47 条

[1]

Conn P.M., Crowley W.F., Gonadotropin-releasing hormone and its analogues, N. Engl. J. Med., 324, pp. 93-103, (1991)

[2]

Bergquist C., Nillius S.J., Wide L., Inhibition of ovulation in women by intranasal treatment with a luteinizing hormone-releasing hormone agonist, Contraception, 19, pp. 497-502, (1979)

[3]

Matta H.M., Shaw R.W., Burford G.D., Endocrinologic and clinical evaluation following a single administration of a gonadotropin-releasing hormone agonist (Zoladex), in depot formulation, to premenopausal women, Fertil. Steril., 49, (1988)

[4]

Zorn J.R., Soubrane O., Siboni O., Papageorgiou G., Medical reversible castration with D-Trp6 -LHRH microcapsules for the treatment of endometriosis, Contr. Gynec. Obstet., 16, pp. 254-259, (1987)

[5]

van Leusden H.A.I.M., Dogterom A.A., Rapid reduction of uterine leiomyomas with monthly injections of D-Trp6 -GnRH, Gynecol. Endocrinol., 2, pp. 45-51, (1988)

[6]

Zorn J.R., Barata M., Brami C., Ovarian stimulation for in vitro fertilisation combining administration of gonadotrophins and blockade of the pituitary with D-Trp6-LHRH microcapsules: pilot studies with two protocols, Hum. Reprod., 3, pp. 235-239, (1988)

[7]

Freude G., Artner B., Leodolter S., First experiences and results with the GnRH agonist Decapeptyl CR in the treatment of PCO patients, Gynecol. Endocrinol., 2, (1988)

[8]

Parmar H., Rustin G., Lightman S.L., Response to D-Trp6-luteinizing hormone-releasing hormone (Decapeptyl) microcapsules in advanced ovarian cancer, Br. Med. J., 296, (1988)

[9]

Happ J., Schultheiss H., Jacobi G.H., Pharmacodynamics, pharmacokinetics and bioavailability of the prolonged LH-RH agonist Decapeptyl SR, Hormonal Manipulation of Cancer: Peptides, Growth Factors and New (Anti) Steroidal Agents, pp. 249-253, (1987)

[10]

Mason-Garcia M., Vigh S., Comaru-Schally A.M., Radioimmunoassay for 6-D-Tryptophan analog of luteinizing hormone-releasing hormone: measurement of serum levels after administration of long acting microcapsules formulation, Proc. Natl. Acad. Sci. USA, 82, pp. 1547-1551, (1985)

← 1 2 3 4 5 →